The company shared interim results from an ongoing Phase II trial examining its recombinant antibody fusion protein.

Millions of patients are hospitalized for acute heart failure (AHF) every year throughout ... of HF is projected to increase. Yet, initial treatment of AHF today is similar to 40 years ago.

He lives it every day, as he and his fellow researchers study and reprogram the potential of the blood to treat disease, specifically heart failure in children. Building on the work of Dr. Shinya ...

Alleviant Medical announced that it received FDA investigational device exemption and breakthrough device designation for its atrial shunt.

"These findings reinforce the use of dapagliflozin, 10 mg, or other SGLT2 inhibitors when the therapeutic goal is to reduce ...

Alleviant Medical announced today that it brought in $90 million to fund the second pivotal trial of its atrial shunt ...

CONGESTIVE HEART FAILURE. MEYER SAYS HE’S BEEN LOOKING TO JOIN A RESEARCH STUDY TO SEE IF HE CAN HELP FIND A BETTER TREATMENT FOR HEART FAILURE, SO I’M REALLY EXCITED ABOUT IT BECAUSE I THINK ...

"Microtech commences human trials of microsensor for heart failure treatment" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site ...

Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing ...

reduced ejection fraction. Women present differently with heart failure and respond differently to certain treatments. Women with heart failure with preserved ejection fraction have sex-specific ...

With the growing trend of heavier cattle and carcass weights, packers are seeing higher rates of bovine congestive heart ...

Kerenida is currently approved to slow the progression chronic kidney disease associated with type 2 diabetes.